About the AMR local indicators
Data have been uploaded across six domains: The AMR local indicators are produced by the UKHSA.
- Supporting NHS England Initiatives
- Antimicrobial Resistance (AMR)
- Antibiotic Prescribing
- Healthcare-Associated Infections (HCAI)
- Infection Prevention and Control (IPC)
- Antimicrobial stewardship (AMS)
Antibiotic prescribing and antibiotic resistance are inextricably linked, as overuse and incorrect use of antibiotics are major drivers of resistance. AMR local indicators are publically available data intended to raise awareness of antibiotic prescribing, AMR, HCAI, IPC and AMS; and to facilitate the development of local action plans. The data published in this tool may be used by healthcare staff, commissioners, directors of public health, academics and the public to compare the situation in their local area to the national picture.
For further information about this profile, please click here to download the user guide.
Updated indicators
June 2024 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -
Topic: Healthcare Associated Infections Area: Acute Trusts, Sub ICBs up to April 2024
Area – ICB sub-locations
- C. difficile infection counts and 12-month rolling rates all cases, by Sub ICB Location (SICBL) and month
- C. difficile infection counts and 12-month rolling rates community onset-community associated, by Sub ICB Location (SICBL) and month
- C. difficile infection counts and 12-month rolling rates community onset-healthcare associated, by Sub ICB Location (SICBL) and month
- E. coli bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
- E. coli bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
- E. coli bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
- Klebsiella spp. bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
- Klebsiella spp. bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
- Klebsiella spp. bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
- MRSA bacteraemia cases all counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
- MRSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
- MRSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
- MSSA bacteraemia cases counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
- MSSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
- MSSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
- P. aeruginosa bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
- P. aeruginosa bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
- P. aeruginosa bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
Area – Acute Trusts
- C. difficile infection counts and 12-month rolling rates of all cases, by reporting acute trust and month
- C. difficile infection counts and 12-month rolling rates of community onset-healthcare associated, by reporting acute trust and month
- C. difficile infection counts and 12-month rolling rates of hospital onset-healthcare associated cases, by reporting acute trust and month
- E. coli bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
- E. coli bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
- E. coli bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
- Klebsiella spp. bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
- Klebsiella spp. hospital-onset cases counts and 12-month rolling rates, by reporting acute trust and month
- Klebsiella spp. bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
- MRSA total cases counts and 12-month rolling rates, by reporting acute trust and month
- MRSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
- MRSA cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
- MSSA bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
- MSSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
- MSSA total cases counts and 12-month rolling rates, by reporting acute trust and month
- P. aeruginosa bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
- P. aeruginosa bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
- P. aeruginosa bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
- C. difficile toxin tests per 1,000 bed-days carried out by reporting acute trust and quarter
- Blood culture sets per 1,000 bed-days performed by reporting acute trust and quarter
Topic: Antimicrobial Resistance Area: ICB sub-locations level covering upto Q1 2024 period
1. E. coli, blood, testing, carbapenem, quarterly, percentage
2. E. coli, blood, testing, 3rd generation cephalosporin, quarterly, percentage
3. E. coli, blood, testing, Ciprofloxacin, quarterly, percentage
4. E. coli, blood, testing, Gentamicin, quarterly, percentage
5. E. coli, blood, testing, Piperacillin/Tazobactam, quarterly, percentage
6. E. coli, urine, testing, trimethoprim, quarterly, percentage, community
7. E. coli, urine, resistance, trimethoprim, quarterly, percentage, community
8. E. coli, urine, testing, nitrofurantoin, quarterly, percentage, community
9. E. coli, urine, resistance, nitrofurantoin, quarterly, percentage, community
10. E.coli, blood, resistance, 1 Antibiotics, rolling quarterly, percentage
11. E.coli, blood, resistance, 3 or more antibiotics classes, rolling quarterly, percentage
12. E.coli, blood, resistance, 3rd generation cephalosporin, rolling quarterly, percentage
13. E.coli, blood, resistance,Ciprofloxacin, rolling quarterly, percentage
14. E.coli, blood, resistance, Gentamicin, rolling quarterly, percentage
15. E.coli, blood, resistance, Piperacillin/Tazobactam, rolling quarterly, percentage
Topic: Antimicrobial Resistance Area: Acute Trusts covering upto Q1 2024 period
1. E. coli, blood, testing, Gentamicin, quarterly, percentage
2. E. coli, blood, testing, carbapenem, quarterly, percentage
3. E. coli, blood, testing, Ciprofloxacin, quarterly, percentage
4. E. coli, blood, testing, piperacillin/tazobactam, quarterly, percentage
5. E. coli, blood, testing, 3rd generation cephalosporin, quarterly, percentage
6. E.coli, blood, resistance, Ciprofloxacin, rolling quarterly, percentage
7. E.coli, blood, resistance, 3rd generation cephalosporin, rolling quarterly, percentage
8. E.coli, blood, resistance, piperacillin/tazobactam, rolling quarterly, percentage
9. E. coli, blood, resistance, Gentamicin, quarterly, percentage
May 2024 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -
Topic: Healthcare Associated Infections Area: Acute Trusts, Sub ICBs up to March 2024
These indicators have been updated: 91933 92039 92040 92041 92081 92178 92193 93004 93005 93006 93007 93058 93059 93060 93061 93062 93063 93064 93065 93066 93067 93068 93069 93070 93361 93364 93365 93368 93369 93373 93374 93405 93410 93415 93420 93427
April 2024 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -
Topic: Antibiotic Prescribing Area: ICB sub-locations up to Q4 2023/24 (cy)
- Total number of prescribed antibiotic items per STAR-PU by quarter
- Total number of prescribed antibiotics items per 1000 resident individuals by quarter
- Percentage of broad - spectrum prescribed antibiotics items (cephalosporin, quinolone and co- amoxiclav class) by quarter
- Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin
- Twelve-month rolling total number of prescribed antibiotic items per 1000 resident individuals per day
- Twelve-month rolling total number of prescribed antibiotic items per STAR-PU
- Twelve-month rolling percentage of prescribed antibiotic items from cephalosporin, quinolone and co-amoxiclav class
Topic: Antibiotic Prescribing Area: GP up to Q4 2023/24 (cy)
- Percentage of broad-spectrum prescribed antibiotic items (cephalosporin, quinolone and co-amoxiclav class) by quarter
- Total number of prescribed antibiotic items per 1000 registered patients by quarter
- Total number of prescribed antibiotic items per STAR-PU by quarter
- Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin
“The method of consultations in the community during the COVID-19 pandemic (from 2020) is likely to be different from the pre-pandemic period. Therefore, comparisons of the data before and during the pandemic should be treated with caution. Also please note that total antibacterial items have reduced over the COVID-19 period and will have had subsequent impacts on antibiotic proportions, where total antibacterial items has been used as the denominator.”
Topic: Antibiotic Prescribing Area: Acute Trusts upto Q4 2023/24 (fy)
- Total antibiotic prescribing DDDs per 1000 admissions; by quarter and trust
AWaRe and broad-spectrum prescribing
- Carbapenem prescribing DDDs per 1000 admissions; by quarter and acute trust
- Proportion of total antibiotic prescribing from the "Access" category of the nationally adapted WHO AWaRe index; by quarter and acute trust
- Proportion of total antibiotic prescribing from the "Reserve" category of the nationally adapted WHO AWaRe index
- Proportion of total antibiotic prescribing from the "Watch" category of the nationally adapted WHO AWaRe index
- Proportion of total antibiotic prescribing from the "Watch" and "Reserve" categories of the nationally adapted WHO AWaRe index
- Antibiotic prescribing from the “Watch” and “Reserve” categories of the nationally adapted WHO AWaRE index; DDDs per 1000 admissions by quarter and trust
Supporting IVOS CQUIN
- Intravenous antibiotic prescribing; DDDs per 1000 admissions by month and NHS Acute Trust
- Proportion of total antibiotic prescribing administered intravenously; by month and NHS Acute Trust
Interventions to reduce AMR
There are a number of actions that can be taken to reduce the burden of AMR. These include improved antibiotic prescribing as well as enhanced infection prevention and control, both for healthcare-associated and community-onset infections. The AMR resource handbook identifies current national policy, guidance and supporting materials in relation to antimicrobial stewardship and the infection prevention and control of healthcare associated infections in order to aid the reduction of antimicrobial resistance.